ClinicalTrials.gg
Not yet recruitingNCT06738901Updated Dec 18, 2024

An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients

A Phase 3 interventional study of SKP-0141 in Hemophilia A, Severe, sponsored by SK Plasma Co., Ltd.. Not yet recruiting. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by SK Plasma Co., Ltd. (formerly part of SK Chemicals Co., Ltd.) · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Study summary

This is a prospective, multicenter, open-label study to assess efficacy, safety, pharmacokinetics (PK), and immunogenicity of human plasma-derived Factor VIII (FVIII) in previously treated patients (PTPs) with severe hemophilia A. Overall, 55 male PTPs aged 12 to 65 years old with a FVIII level of \< 1% and at least 150 treatment exposure days (EDs) with a previous FVIII product will be enrolled. Patients will receive SKP-0141 at a dose of 25 to 50 IU/kg every second day or 3 times per week for at least 50 EDs and/or 6 months from the start of prophylactic treatment. Efficacy of SKP-0141 will be primarily evaluated in bleeding prophylaxis with annualized bleeding rate from start of treatment and until end of treatment (Visit 10).

02

Conditions studied

  • Hemophilia A, Severe

Browse trials for

Keywords

  • Congenital hemophilia A
  • Prophylaxis
  • On-demand
  • FVIII concentrate
  • Hemophilia A
03

In context

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

This study's planned enrollment of 55 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

SK Plasma Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A patient or parent/legal guardian who is capable of giving signed
  • Patients assigned male at birth and must be 12 to 65 years old at the time of Screening
  • Diagnosis of severe congenital hemophilia A, defined as an FVIII level of \<1% as documented in the patient's medical records at the time of Screening
  • Patients who have received or are currently receiving plasma-derived and/or recombinant FVIII products and have had at least 150 EDs with a FVIII product
  • Patients who can produce viable sperm and have a partner of must agree to take appropriate measures consistently during the study, starting at Screening and until 30 days after the end of study

Exclusion criteria

Exclusion Criteria:

  • Any history of or current FVIII inhibitors or any first order family history of FVIII inhibitors in terms of detectable FVIII inhibitors (ie, ≥0.6 Bethesda Units [BU]) using the Nijmegen-modification of the Bethesda assay
  • Any known congenital or acquired coagulation disorder other than the congenital hemophilia A
  • Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and arterial embolus within 3 months prior to Visit 1
  • Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Visit 1
  • Has been tested positive for with a ≤200/μL at Screening (if available, surface antigen, or virus antibodies, and/or positive hepatitis B virus deoxyribonucleic acid/HCV ribonucleic acid at Screening
  • count \<100 000/μL at Screening
  • Patients with serum or serum alanine aminotransferase values >5 × the or serum creatinine values >2 × ULN at Screening
  • Patients who are currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic treatment within 3 months prior to Visit 1
  • Use of any other medicinal product, cryoprecipitate, whole blood, or plasma within 30 days or 5 half-lives prior to Visit 1
  • Known or suspected to any FVIII product or their
  • Has a physical, medical, or psychological condition, that in the opinion of the PI, may interfere with the evaluation of the study.
  • Are study site personnel directly affiliated with this study and their immediate families
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Prophylactic treatment

    Biological: SKP-0141

Interventions

  • BiologicalSKP-0141

    Human plasma-derived coagulation factor VIII concentrate

06

What researchers measure

Primary outcomes

  1. Annualized bleeding rate

    Efficacy of SKP-0141 in bleeding prophylaxis in previously treated patients with severe hemophilia A based on the number of bleeding episodes per year

    Time frame: Up to 25 weeks

Secondary outcomes

  1. Hemostatic response

    Efficacy of SKP-0141 for the treatment of breakthrough bleeding episodes using a 4-point scale in previously treated patients with severe hemophilia A

    Time frame: Up to 25 weeks

  2. Consumption of SKP-0141 required for prophylaxis

    Dose of SKP-0141 injections (IU/kg/year and IU/kg/month) required for prophylaxis in previously treated patients with severe hemophilia A

    Time frame: Up to 25 weeks

  3. Consumption of SKP-0141 required for on-demand treatment

    Dose/number of SKP-0141 injections (IU/kg/bleed) required for treatment of bleeding episodes in previously treated patients with severe hemophilia A

    Time frame: Up to 25 weeks

  4. Peak plasma concentration (Cmax)

    Maximum plasma concentration of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  5. Time to reach peak plasma concentration (Tmax)

    Time to reach peak plasma concentration of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  6. Area under the plasma concentration versus time curve (AUC)

    Area under the plasma concentration versus time curve in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  7. Half-life (T1/2)

    Half-life of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  8. Total plasma clearance (CL)

    Total plasma clearance of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  9. Elimination constant (Kel)

    Elimination rate constant of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  10. Volume of distribution (Vd)

    Volume of distribution of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  11. Mean residence time (MRT)

    Mean residence time in vivo of SKP-0141 in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  12. Incremental in vivo recovery (IVR)

    Incremental in vivo recovery (IVR) in previously treated patients with severe hemophilia A

    Time frame: At 1 week and 25 weeks

  13. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events in previously treated patients with severe hemophilia A

    Time frame: Up to 26 weeks

  14. Incidence of serious adverse events (SAEs)

    Incidence of serious adverse events in previously treated patients with severe hemophilia A

    Time frame: Up to 26 weeks

  15. Incidence of adverse events of special interest (AESIs)

    Incidence of adverse events of special interest in previously treated patients with severe hemophilia A

    Time frame: Up to 26 weeks

  16. Incidence of adverse events (AEs)

    Incidence of adverse events in previously treated patients with severe hemophilia A

    Time frame: Up to 26 weeks

  17. Incidence of clinically significant changes

    Safety and tolerability of SKP-0141 in previously treated patients with severe hemophilia A based on the incidence of clinically significant changes from baseline in safety laboratory evaluations (hematology, serum chemistry, and urinalysis), vital signs (pre- and post-injection), physical examinations, and ECG

    Time frame: Up to 25 weeks

  18. Incidence of FVIII inhibitor formation

    Immunogenicity of SKP-0141 from incidence of FVIII inhibitor formation (≥0.6 Bethesda Units) calculated using the Nijmegen-modified Bethesda assay in previously treated patients with severe hemophilia A

    Time frame: Up to 25 weeks

Other outcomes

  1. Hemostatic response in surgical prophylaxis

    Hemostatic response (efficacy) of SKP-0141 in surgical prophylaxis in previously treated patients with severe hemophilia A

    Time frame: Perioperatively/Periprocedurally

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jul 2026, 16 months later.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 16 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2024
First posted
Dec 18, 2024
StartEst.
Mar 31, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06738901
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Mar 31, 2025 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Dec 18, 2024

Study contacts

Byung Nam Chung
Contact
byung-nam.chung@sk.com
82-2-2008-2567
Garam Kim, M.S.
Contact
kgram@sk.com
+82-2-2008-2062

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion